Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
14 studies found for:    breast cancer targeted therapy HER2-negative | Open Studies
Show Display Options
Rank Status Study
1 Recruiting DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs
Conditions: HER2-negative Metastatic Breast Cancer;   HER2-positive Circulating Tumor Cells
Interventions: Drug: standard chemo- or endocrine therapy;   Drug: standard chemo- or endocrine therapy + Lapatinib
2 Recruiting Palbociclib With Everolimus + Exemestane In BC
Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Hormone Receptor (HR)-Positive Breast Cancer
Interventions: Drug: Palbociclib;   Drug: Everolimus;   Drug: Exemestane
3 Recruiting Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
Condition: Metastatic Triple Negative Breast Cancer
Intervention: Drug: Combination of Veliparib + Lapatinib
4 Recruiting T-Cell Therapy for Advanced Breast Cancer
Conditions: Breast Cancer;   Metastatic HER2-negative Breast
Interventions: Drug: Cyclophosphamide;   Biological: Mesothelin-targeted T cells;   Drug: AP1903
5 Recruiting Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
Conditions: HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage III Breast Cancer
Interventions: Biological: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine;   Other: Laboratory Biomarker Analysis
6 Not yet recruiting MEtronomic TrEatment Option in Advanced bReast cAncer
Condition: Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Cyclophosphamide;   Drug: Capecitabine;   Drug: Vinorelbine
7 Recruiting Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
Conditions: Primary Non-metastatic Breast Cancer;   Who Remain Disease-free
Interventions: Drug: Everolimus;   Drug: Placebo
8 Recruiting PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)
Condition: Metastatic Breast Cancer
Interventions: Drug: PQR309;   Drug: Eribulin
9 Recruiting Exosomal and Free Extracellular RNAs and Proteins as Predictive. ICORG 10-15, V2
Conditions: Breast Cancer;   HER2 Positive Breast Cancer;   HER2 Negative Breast Cancer
Intervention: Other: Biomarker Analysis
10 Recruiting Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer
Condition: Breast Cancer
Interventions: Drug: ddAC-CP-Olaparib;   Drug: ddAC-mini CTC
11 Recruiting Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: epirubicin hydrochloride;   Drug: carboplatin;   Procedure: therapeutic conventional surgery;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
12 Recruiting Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: MK-3475
13 Recruiting CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer
Conditions: Metastatic Breast Adenocarcinoma;   Breast Cancer
Intervention: Drug: CR1447
14 Recruiting Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab (With and Without Docetaxel) in Participants With HER2-Positive Breast Cancer and Atezolizumab With Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer
Condition: HER2 Positive Breast Cancer
Interventions: Drug: Atezolizumab;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Pertuzumab;   Drug: Trastuzumab;   Drug: Trastuzumab emtansine;   Drug: Doxorubicin;   Drug: Cyclophosphamide

Study has passed its completion date and status has not been verified in more than two years.